Chemistry:Selepressin

From HandWiki
Short description: Chemical compound
Selepressin
Selepressin.svg
Clinical data
Other namesH-Cys(1)-Phe-Ile-hGln-Asn-Cys(1)-Pro-Orn(iPr)-Gly-NH2
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC46H73N13O11S2
Molar mass1048.29 g·mol−1
3D model (JSmol)

Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.[1][2][3][4]

The Phase 2b/3 adaptive trial (SEPSIS-ACT) was terminated in February 2018 for futility. The trial was halted prior to the initiation of the arm for the highest dosing regimen of 5.0 ng/kg/min.[5]

References

  1. Levin, Jeremy I (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2. https://books.google.com/books?id=t13YBAAAQBAJ&pg=PA313. 
  2. Vincent, Jean-Louis (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2. https://books.google.com/books?id=hLC_pIcizCgC&pg=PA80. 
  3. Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. 2 September 2008. pp. 427–. ISBN 978-3-540-77290-3. https://books.google.com/books?id=KXEdgwRXULMC&pg=PA427. 
  4. "Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension". The Journal of Pharmacology and Experimental Therapeutics 337 (3): 786–96. June 2011. doi:10.1124/jpet.111.178848. PMID 21411496. 
  5. Clinical trial number NCT02508649 for "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial" at ClinicalTrials.gov